Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R…